First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

BACKGROUND: Although the clinical application of osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been a new step forward in the first-line treatment of non-small cell lung cancer (NSCLC), an increasing number of patients with progression on...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Naifu, Li, Jianghua, Zhang, Jian, Dai, Jie, Liu, Zhulin, Ding, Zhenyu, Wang, Yubo, Zhu, Mengxiao, Hu, Chen, Han, Rui, Tang, Huan, Li, Li, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661557/
https://www.ncbi.nlm.nih.gov/pubmed/36387609
http://dx.doi.org/10.1177/11795549221134735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661557/
https://www.ncbi.nlm.nih.gov/pubmed/36387609
http://dx.doi.org/10.1177/11795549221134735

Ejemplares similares